Japanese (NIKKEI) Drug Retail Industry Analysis

Industry Valuation and Performance

Has the Japanese Drug Retail Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 08 Jun 2026	JP¥3.9t	JP¥7.7t	JP¥252.7b	14.4x	15.3x	0.5x
Wed, 06 May 2026	JP¥4.0t	JP¥7.6t	JP¥251.2b	15.9x	15.8x	0.5x
Fri, 03 Apr 2026	JP¥4.4t	JP¥7.2t	JP¥222.1b	16.3x	20x	0.6x
Sun, 01 Mar 2026	JP¥4.6t	JP¥7.2t	JP¥220.5b	17.3x	20.8x	0.6x
Tue, 27 Jan 2026	JP¥4.1t	JP¥7.2t	JP¥224.2b	14.9x	18.1x	0.6x
Thu, 25 Dec 2025	JP¥4.3t	JP¥7.1t	JP¥222.7b	14.4x	19.2x	0.6x
Sat, 22 Nov 2025	JP¥5.2t	JP¥8.8t	JP¥243.6b	15.3x	21.3x	0.6x
Mon, 20 Oct 2025	JP¥4.8t	JP¥8.7t	JP¥241.0b	15.2x	20.1x	0.6x
Wed, 17 Sep 2025	JP¥5.1t	JP¥8.6t	JP¥239.0b	15.5x	21.6x	0.6x
Fri, 15 Aug 2025	JP¥5.1t	JP¥8.6t	JP¥238.2b	14.8x	21.4x	0.6x
Sun, 13 Jul 2025	JP¥5.0t	JP¥8.5t	JP¥217.2b	15x	22.9x	0.6x
Tue, 10 Jun 2025	JP¥4.7t	JP¥8.5t	JP¥213.3b	15.6x	22.1x	0.6x
Thu, 08 May 2025	JP¥4.7t	JP¥8.4t	JP¥209.5b	18.4x	22.6x	0.6x
Sat, 05 Apr 2025	JP¥4.1t	JP¥8.3t	JP¥216.3b	16.8x	19x	0.5x
Mon, 03 Mar 2025	JP¥3.9t	JP¥8.2t	JP¥217.9b	16.7x	18x	0.5x
Wed, 29 Jan 2025	JP¥4.0t	JP¥8.2t	JP¥217.8b	18x	18.3x	0.5x
Fri, 27 Dec 2024	JP¥3.6t	JP¥8.1t	JP¥217.7b	15.9x	16.7x	0.5x
Sun, 24 Nov 2024	JP¥3.6t	JP¥8.1t	JP¥219.3b	15.9x	16.5x	0.4x
Tue, 22 Oct 2024	JP¥3.9t	JP¥8.0t	JP¥222.4b	16.3x	17.4x	0.5x
Thu, 19 Sep 2024	JP¥3.9t	JP¥7.9t	JP¥218.8b	16.6x	17.7x	0.5x
Sat, 17 Aug 2024	JP¥3.9t	JP¥7.9t	JP¥220.5b	16.6x	17.5x	0.5x
Mon, 15 Jul 2024	JP¥4.0t	JP¥7.9t	JP¥221.4b	16.7x	17.9x	0.5x
Wed, 12 Jun 2024	JP¥3.9t	JP¥7.8t	JP¥227.1b	16.4x	17x	0.5x
Fri, 10 May 2024	JP¥4.1t	JP¥7.7t	JP¥225.3b	17.2x	18.3x	0.5x
Sun, 07 Apr 2024	JP¥4.2t	JP¥7.7t	JP¥224.6b	16.3x	18.9x	0.6x
Tue, 05 Mar 2024	JP¥4.2t	JP¥7.6t	JP¥223.3b	14.7x	19x	0.6x
Thu, 01 Feb 2024	JP¥4.4t	JP¥7.6t	JP¥219.3b	14.6x	20.2x	0.6x
Sat, 30 Dec 2023	JP¥4.4t	JP¥7.5t	JP¥218.2b	14.9x	20x	0.6x
Mon, 27 Nov 2023	JP¥4.3t	JP¥7.5t	JP¥215.5b	15.4x	19.9x	0.6x
Wed, 25 Oct 2023	JP¥4.1t	JP¥7.4t	JP¥211.7b	15.7x	19.4x	0.6x
Fri, 22 Sep 2023	JP¥4.2t	JP¥7.3t	JP¥209.7b	16.5x	20.1x	0.6x
Sun, 20 Aug 2023	JP¥4.7t	JP¥7.7t	JP¥221.6b	18x	21.4x	0.6x
Tue, 18 Jul 2023	JP¥4.6t	JP¥7.8t	JP¥221.9b	17.3x	20.7x	0.6x
Thu, 15 Jun 2023	JP¥4.6t	JP¥7.7t	JP¥221.6b	17.5x	20.8x	0.6x

Current Industry PE

Investors are pessimistic on the Japanese Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 15.3x which is lower than its 3-year average PE of 19.3x.

The industry is trading close to its 3-year average PS ratio of 0.55x.

Past Earnings Growth

The earnings for companies in the Drug Retail industry have grown 4.5% per year over the last three years, while revenues have remained mostly flat.
This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Comparison

How does Japanese Drug Retail compare with similar industries?


JP Market	-0.18%
Consumer Staples	-2.32%
Food and Staples Retail	-0.62%
Drug Retail	1.20%
Food Retail	-0.21%
Big Box Super Stores	-2.14%
Food Distributors	-4.84%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
3391 Tsuruha Holdings	JP¥2.05k	5.3% +JP¥46.7b	-9.7%	PE21.8x
9989 SundrugLtd	JP¥3.87k	7.6% +JP¥31.8b	-12.4%	PE14.4x
7649 Sugi HoldingsLtd	JP¥2.93k	6.3% +JP¥31.5b	-7.7%	PE11.8x
3088 MatsukiyoCocokara	JP¥2.36k	3.3% +JP¥29.9b	-16.9%	PE16.6x
3349 COSMOS Pharmaceutical	JP¥6.06k	4.0% +JP¥18.3b	-31.1%	PE15.3x

New minor risk - Dividend sustainability

The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (12% operating cash flow to total debt). High level of non-cash earnings (25% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.

Japanese (NIKKEI) Drug Retail Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Qol Holdings Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026

Ain Holdings Ups Profit Forecast and Plans ¥100 Dividend on Sakura Pharmacy Integration

High number of new directors

Sundrug Co.,Ltd. to Report Q1, 2027 Results on Aug 14, 2026

Now 23% undervalued after recent price drop

Investors Can Find Comfort In Miahelsa Holdings' (TSE:7129) Earnings Quality

Sugi Holdings Co.,Ltd. to Report Q1, 2027 Results on Jul 09, 2026

Upcoming dividend of JP¥37.50 per share

Upcoming dividend of JP¥45.00 per share

MatsukiyoCocokara & Co. (TSE:3088) Just Released Its Yearly Earnings: Here's What Analysts Think

Chukyoiyakuhin Co.,Ltd., Annual General Meeting, Jun 25, 2026

Full year 2026 earnings released: EPS: JP¥36.61 (vs JP¥43.18 in FY 2025)

New minor risk - Dividend sustainability